港股異動 | 麗珠醫藥漲逾3% 績後多家機構看好
格隆匯4月23日丨麗珠醫藥(1513.HK)現報34.8港元,漲3.11%,暫成交7597萬港元,最新總市值325億港元。麗珠醫藥4月20日晚間發公告稱,2020年第一季度,公司實現營業收入25.05億元人民幣,同比減少3.94%;歸屬於上市公司股東的淨利潤3.99億元,同比增長1.68%。績後大摩發研報指,麗珠醫藥今年首季表現穩固,診斷試劑及設備業務銷售前景良好,將2020至2022年盈利預測提升10%至14%。目標價由28.2港元上調至32.3港元,評級“與大市同步”。交銀國際亦稱,麗珠醫藥第1季銷售收入同比下降3.9%,扣除非後歸母淨利潤同比增22.6%,主要由於其產品結構重組、毛利率的顯著改善,以及銷售費用的下降。重申“買入”評級,目標價33.4港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.